News
22x Cost Advantage, 70% Revenue Share-Why Small Molecules are Def
4+ hour, 8+ min ago (184+ words) NEW YORK, NY, UNITED STATES, May 19, 2026 /EINPresswire. com/ -- "The Future of Small Molecules-Why Chemistry is Far from Dead," - The recent webinar by Stellarix delved into why chemistry is thriving at the cutting edge of science and remains strategically relevant in…...
Organoids: AI meets the end of animal testing
2+ hour, 9+ min ago (291+ words) Biopharma company MSD has taken considered bets on healthcare AI, from drug discovery platforms to diagnostics. Here's why the team's AI lead, David Rubin, sees tiny human tissue models as the next emerging area. The Global Health Innovation Fund had…...
Sino Biological Launches XPress MAX" Cell-Free Protein Synthesis Kit, Accelerating AI-Powered High-Throughput Antibody Drug Discovery
2+ hour, 42+ min ago (129+ words) PA Media Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions Gen Script Launches Turbo CHO" Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class Sino Biological's Launch of Swift Fluo" TR-FRET Kits Pioneers…...
AI-designed viral vectors achieve 50-fold brain enrichment over AAV9
2+ hour, 22+ min ago (537+ words) Preclinical findings from White Lab Genomics demonstrate that AI-designed viral vectors achieved approximately 50-fold higher brain DNA enrichment than AAV9 following intravenous injection in mice, while remaining undetectable in the liver." White Lab Genomics has announced new preclinical data showing that…...
New Anti-Mesothelioma Compounds from Paramyrothecium sp.
2+ hour, 10+ min ago (313+ words) This discovery offers a beacon of hope in tackling mesothelioma, a cancer often linked to asbestos exposure with a poor prognosis and limited response to conventional chemotherapies. The unique chemical scaffolds presented by paramyfurans and paramylactone provide new templates for…...
SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting
21+ hour ago (316+ words) Presentation details are as follows: Title: First-in-Human Clinical Evaluation of ST-01156, an Optimized and Selective Degrader of RNA-Binding Motif 39 (RBM39): A Phase 1 Study in Advanced Solid Malignancies with a Focus on RBM39-Dependent Cancers Presenter/Authors: Eric K. Rowinsky, Gregory M. Cote, George D. Demetri,…...
Sandbox AQ Brings Drug Discovery Models To Claude
11+ hour, 53+ min ago (211+ words) The following table highlights the contrast between the traditional approach and the new integrated model: The primary driver behind this collaboration is the democratization of advanced research. Many pharmaceutical and biotechnology organizations face a "talent crunch," where there are simply…...
MIDAS platform accelerates protein engineering through rapid PCR-based screening
5+ hour, 52+ min ago (379+ words) Proteins are critical to life " and to industry. There are countless proteins that could be engineered to treat and even cure serious diseases and cellular dysfunctions. Industrial applications are similarly promising, with proteins increasingly used as enzymes in food manufacturing…...
Galux Shows Broadest Target Coverage in Comparative De Novo Antibody Design Study
19+ hour ago (561+ words) Yahoo Finance Oops, something went wrong U. S. markets open in 9h 19m Galux Shows Broadest Target Coverage in Comparative De Novo Antibody Design Study Across nine publicly comparable targets from recent de novo antibody design studies, Galux Design identified experimentally validated binders for…...
Major breakthrough of Sanyou Biopharmaceuticals AI-STAL
22+ hour ago (832+ words) SHANGHAI, May 18, 2026 /PRNewswire/ " Sanyou Biopharmaceuticals announced today that its independently developed AI-STAL has undergone a significant upgrade, successfully achieving a qualitative leap from "molecular treasure trove" to "intelligent engine", marking the company's entry into a new era of intelligence in…...